863585-88-0Relevant academic research and scientific papers
IMPROVED SOLUBILITY FOR TARGET COMPOUNDS
-
Page/Page column 93; 96; 97, (2017/03/21)
The present disclosure relates to compounds having an improved solubility thereby increasing their bioavailability, lower dosages, etc. The target compounds, may include but are not limited to, macrophage migration inhibitory factor (MIF) inhibitors, epid
PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF
-
Page/Page column 56, (2010/11/24)
The present invention provides a pyarzoloquinolone derivative having kinase inhibitory activity. The derivative is represented by the formula: wherein R1 is an aryl group which may be substituted, or an aromatic heterocyclic group which may be
